Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | PACE: prognostic and predictive biomarkers in ER+/HER2- advanced breast cancer

Guilherme Nader-Marta • 13 Dec 2024
SABCS 2024
Breast Cancer
PACE

Guilherme Nader-Marta, MD, Dana-Farber Cancer Center, Boston, MA, gives an overview of two key studies from the PACE trial (NCT03147287), which explored biomarkers in ER+/HER2- metastatic breast cancer. The first examines thymidine kinase activity (TKa) dynamics and their prognostic value, showing that early TKa changes predict distinct outcomes. The second evaluates DNADX, a machine learning approach using ctDNA data, which identified five tumor subtypes with implications for prognosis and treatment benefit. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guilherme Nader-Marta

Distinct clinical and molecular features of metastatic lobular breast cancer
3:33
Distinct clinical and molecular features of metastatic lobular breast cancer
Guilherme Nader-Marta • 10 Dec 2025
The impact of pregnancy on recurrence scores in ER+/HER2- breast cancer
3:08
The impact of pregnancy on recurrence scores in ER+/HER2- breast cancer
Guilherme Nader-Marta • 13 Dec 2024
PRISMA: observing PSMA expression in metastatic TNBC
3:05
PRISMA: observing PSMA expression in metastatic TNBC
Guilherme Nader-Marta • 3 Jun 2023
Precision medicine for metastatic triple-negative breast cancer
1:07
Precision medicine for metastatic triple-negative breast cancer
Guilherme Nader-Marta • 3 Jun 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals